Related by context. All words. (Click for frequent words.) 82 Drug Candidate 79 Kinase Inhibitor 78 RNAi Therapeutics 78 Initiates Clinical Trial 78 Initiates Phase II 77 Anti Tumor 77 Present Preclinical Data 77 Lung Cancer Drug 77 Initiates Clinical 77 Completes Patient Enrollment 77 Recombinant Human 77 Files IND 77 Antigen Specific 76 Presents Preclinical Data 76 Small Molecule 76 Receives Milestone Payment 76 Receives Orphan Drug Designation 76 Monoclonal Antibody 76 Meets Primary Endpoint 76 siRNA Delivery 76 Aurora Kinase 76 JAK Inhibitor 76 Therapeutic Antibody 76 Novel Therapeutic 76 Angiogenic 76 Tumor Targeting 76 Shows Promising 76 Dendritic Cells 75 Collaborators Publish 75 Patent Covering 75 Prolongs Survival 75 Immunotherapeutic 75 Preclinical Study 75 Phase 2b Trial 75 Presents Preclinical 75 Oligonucleotide 75 Phase 2b Clinical Trial 75 Tyrosine Kinase Inhibitor 75 Novel Antibiotic 75 Neuroprotection 75 RNAi Therapeutic 75 Phase 2a Trial 75 Aptamer 75 Initiates Dosing 75 Mouse Model 74 Rheumatoid Arthritis Drug 74 Novel Oral 74 Achieves Primary Endpoint 74 Investigational Compound 74 Improves Survival 74 DNA Methylation 74 Presents Positive 74 Protein Expression 74 Receives Orphan Drug 74 Lupus Drug 74 FDA Okays 74 Clinical Trial Results 74 Phase 1b Clinical Trial 74 Patient Enrollment 74 Antitumor 74 Breast Cancer Cells 74 Signaling Pathway 74 Preclinical Data 74 Novel Mechanism 74 Shows Promise Against 74 Submits NDA 74 Transdermal Delivery 74 Successfully Completes Phase 74 Transcription Factor 74 Anticancer Drug 74 Develop Novel 74 Initiates Clinical Trials 74 Smooth Muscle 74 Phase III Clinical Trial 74 Demonstrates Significant 74 HDAC Inhibitor 73 Reports Preclinical Data 73 Interferon Gamma 73 Antitumor Activity 73 Cholesterol Lowering Drug 73 Antiangiogenic 73 Therapeutic Vaccine 73 NDA Submission 73 Receptor Agonist 73 Transdermal Patch 73 Phase IIb Clinical Trial 73 Commences Phase 73 Oligonucleotides 73 Gene Silencing 73 Drug Resistant 73 Therapeutic Vaccines 73 Anti Tumor Activity 73 Antisense Drug 73 Drug Shows Promise 73 Completes Enrollment 73 IND Application 73 Epidermal Growth Factor Receptor 73 Milestone Payment 73 Vaccine Adjuvant 73 Prostate Cancer Vaccine 73 Novel Protein 73 Initiate Phase 73 Kinase Inhibitors 73 Initiates Enrollment 73 Inhibits 73 Synthetic Peptide 73 FDA Accepts 73 Immunomedics Announces 73 Clinical Trial Data 73 Cancer Stem Cells 73 Innate Immune 73 IND Filing 73 Investigational Treatment 73 Initiates Phase III 73 Anti CD# Antibody 73 Protease Inhibitor 72 Licenses Novel 72 Nicotine Vaccine 72 Granted Orphan Drug 72 Collaborators Present 72 Patients Treated With 72 Phase IIb Trial 72 Combination REOLYSIN R 72 FDA Clears 72 Progenitor Cells 72 Receives Approvable Letter 72 Tumor Suppressor 72 Demonstrates Potential 72 Therapeutic Potential 72 Immunostimulatory 72 Immunomodulatory 72 Factor Receptor 72 Novel Inhibitor 72 Plasmid DNA 72 Phase 2a Clinical Trial 72 Study Evaluating 72 Initiate Clinical Trial 72 Diabetic Foot Ulcer 72 FDA Approvals 72 Treating Chronic 72 Pharmacokinetic Study 72 Tezampanel 72 Antibody Discovery 72 rxRNA 72 Progenitor Cell 72 Bosutinib 72 AnaSpec Introduces 72 Fast Track Status 72 Gout Drug 72 Polymerase Inhibitor 72 Diagnostic Tests 72 platform HDL Mimetic 72 Personalized Immunotherapy 72 Psoriasis Drug 72 Therapeutic Targets 72 ARRY # 72 Genes Involved 72 Preclinical Models 72 Vaccine Adjuvants 72 Cancer Vaccines 72 Monoclonal 72 Pooled Analysis 72 Antisense Oligonucleotides 72 Malaria Vaccine 72 Recombinant Protein 72 Monoclonal Antibodies 72 Orally Active 72 Epilepsy Drug 72 Gene Mutation 71 Tumor Growth 71 Ebola Vaccine 71 Anticancer Agent 71 Nanoemulsion 71 Adjuvant Chemotherapy 71 Histone Deacetylase 71 Rotavirus Vaccine 71 Demonstrates Efficacy 71 Completes Dosing 71 Granulocyte Colony Stimulating Factor 71 Blood Pressure Drug 71 Phase III Trial 71 Oral Calcitonin 71 Anticancer Compound 71 Genotyping Test 71 Mimetics 71 Anti Angiogenic 71 Chemokine Receptor 71 Skeletal Muscle 71 Antisense 71 Antibody Drug Conjugate 71 Sapacitabine 71 First Patient Treated 71 Pivotal Phase 71 Randomized Phase 71 Avian Influenza Vaccine 71 Protein Synthesis 71 Cell Adhesion 71 Gene Variants 71 Begin Clinical Trials 71 Cell Transplants 71 Renal Cell Carcinoma 71 Drug Prevents 71 Breast Cancer Metastasis 71 Vitro Activity 71 Adjuvant Treatment 71 Dose Escalation 71 Lentiviral 71 Clinical Outcome 71 JAK2 Inhibitor 71 Genetic Variation 71 Pafuramidine 71 Osteoporosis Drug 71 RNA Interference 71 Lymphoid 71 Anti Angiogenesis 71 Submits IND 71 Hsp# Inhibitor 71 BioSante Pharmaceuticals Announces 71 Genetic Mutation 71 Advanced Melanoma 71 Liposomal 71 Inflammatory Arthritis 71 Liver Toxicity 71 Begins Dosing 71 Demonstrates Positive 71 Circulating Tumor Cells 71 Cytotoxicity 71 Mouse Models 71 First Patient Dosed 71 Vaccine Candidate 71 Transfection 71 Diabetic Nephropathy 71 Biomarker Study 71 Brain Metastases 71 Patient Enrolment 71 Drug Fails 71 Commence Phase 71 Disease Progression 71 Molecular Diagnostic 71 Presents Positive Preclinical 71 Cell Proliferation 71 Tumor Cells 71 Phase 2b Study 71 Improve Survival 71 Electroporation 70 Attenuates 70 Gene Variation 70 Arthritis Drug 70 KL4 Surfactant 70 Pegylated 70 Protein Interactions 70 Announces FDA Clearance 70 Drug Combo 70 Targeted Therapy 70 Prodrug 70 Pivotal Phase III 70 Antigens 70 Effectively Treats 70 Combination Treatment 70 Breast Cancer Recurrence 70 Seasonal Influenza Vaccine 70 Diabetic Neuropathy 70 Regenerative Cells 70 Therapeutic Efficacy 70 TB Vaccine 70 Endothelial Cells 70 Fibroblast 70 Patents Covering 70 Commercialize Novel 70 Avian Flu Vaccine 70 Pivotal Study 70 Osteoporosis Treatment 70 Recurrent Breast Cancer 70 Investigational Agent 70 Potent Inhibitor 70 Molecular Diagnostic Test 70 Novel Peptide 70 Immune Responses 70 Obtains Exclusive License 70 Therapeutic Competitors Companies 70 Pivotal Trial 70 Migraine Drug 70 Protein Biomarker 70 Anticancer Drugs 70 Phase III Pivotal 70 Oral Fingolimod 70 CYT# potent vascular disrupting 70 Tumor Targeted 70 Hematopoietic 70 Novel Vaccine 70 Humanized Anti 70 Exclusive License 70 First Patient Enrolled 70 Stem Cell Treatment 70 Phase IIa Clinical Trial 70 Hepatocytes 70 Extracellular Matrix 70 Abstract Accepted 70 Autoimmune Disease 70 Autologous Stem Cell Transplantation 70 Antiviral Activity 70 Multicenter Randomized 70 Novel Method 70 Adenoviral 70 Confirmatory Phase 70 cMET 70 Interferon Alpha 70 Files Patent Application 70 Novel Therapies 70 Metabolic Disorder 70 Oral Formulation 70 Small Molecule Inhibitors 70 Cardiotoxicity 70 Test Detects 70 Severe Sepsis 70 Fungal Infections 70 Inflammatory Markers 70 Protein Kinase 70 Schizophrenia Drug 70 Transcriptome 70 Key Milestones 70 kidney urologic 70 Ridaforolimus 70 Gets FDA Clearance 70 Novel Antibody 70 Kidney Function 70 Submits Response 70 tests miRview TM 70 Receive Milestone Payment 70 Virus Infection 70 Demonstrates Potent 70 Advanced Renal Cell 70 Genetic Disorder 70 Conjugate 70 Initiate Phase III 70 Deforolimus 70 Demonstrates Statistically Significant 70 Mylan Receives Approval 69 Teva Provides Update 69 Novel Compound 69 Renal Cancer 69 Treatment Reduces 69 Novel Compounds 69 Respiratory Virus 69 AVI BioPharma Announces 69 Gastric Cancer 69 Neoadjuvant Chemotherapy 69 Files Investigational 69 Confirms Efficacy 69 Romidepsin 69 Demonstrates Ability 69 FOLOTYN ® 69 Therapeutic Antibodies 69 Bucindolol 69 Human Monoclonal Antibodies 69 Proteasome 69 Anthracycline 69 Potent Antiviral Activity 69 Gene Variant 69 CYP#A# CYP#D# 69 Improves Outcomes 69 Crit Rev 69 Dose Ranging Study 69 Clinical Validation 69 Gamma secretase 69 HIV Integrase 69 Estrogen Receptor 69 Data Suggest 69 Phase III Trials 69 Preclinical Efficacy 69 Trastuzumab DM1 69 Phase Ib Clinical Trial 69 Combination Therapy 69 GRAS Status 69 Sphingomab 69 Inovio Pharmaceuticals 69 Initiates Phase 2b 69 Predict Risk 69 Diamyd Medical Diamyd 69 Announce Collaboration Agreement 69 DiLA2 69 Eluting Stent 69 Adjuvant Therapy 69 Significantly Improves 69 Awarded Qualifying Therapeutic 69 Pralatrexate 69 novel VDA molecule 69 Shows Statistically Significant 69 Sipuleucel T 69 Receptor Antagonist 69 Valortim TM 69 Inhaled Insulin 69 Trial Evaluating 69 Smallpox Vaccine 69 Prospective Randomized 69 Magnetic Nanoparticles 69 Glufosfamide 69 Cyclin Dependent 69 Gene Linked 69 Hematopoietic Stem Cells 69 RNA Interference RNAi 69 Aeolus Pharmaceuticals Announces 69 Signaling Pathways 69 Nasal Powder 69 Adenoma 69 Milestone Payment From 69 Medullary Thyroid Cancer 69 Platelet Derived Growth 69 Cannabinoid 69 Lung Cancer Trial 69 humanized monoclonal 69 Entry Inhibitor 69 Immune Cell 69 Testosterone Patch 69 Therapeutic Effects 69 Genetic Variant 69 Aliskiren 69 Mesenchymal Stem Cells 69 Interferon Beta 69 Zinc Finger 69 Cholesterol Drug 69 Protein Involved 69 Glycosylation 69 Hepatocellular Carcinoma 69 Histone 69 Antiviral Drugs 69 Epitopes 69 Topical Treatment 69 Neural Stem Cells 69 Embryonic Stem Cells 69 Expanded Indication 69 Sangamo BioSciences Announces 69 anionic backbone 69 Survival Benefit 69 Sustained Release 69 Initiates Phase 69 Breast Tumors 69 Announces Poster Presentations 69 Artificial Pancreas 69 Lung Cancer Survival 69 Subunit 69 Apoptotic 69 Nucleoside 69 targeting CD# 69 Safinamide 69 Janus kinase 69 Mg Usa 69 HuMax TAC 69 Bazedoxifene 69 Oxidative Stress 69 Mutational 69 Contrast Agent 69 Preclinical Evaluation 69 Randomized Phase II 69 Cell Differentiation 69 Flamel Technologies Announces 69 Mutagenesis 69 antisense inhibitors 69 Milestone Payments 69 Hedgehog Pathway 69 Genes Linked 69 Shows Promise 69 Anti Inflammatory Drug 69 Fibrinogen 69 Anti Inflammatory 69 Cancer Cells 69 Bone Marrow Stem Cells 69 Blood Thinner 69 Combo Therapy 69 Soft Tissue Sarcoma 69 Statistically Significant 69 Oral Insulin 69 Anthrax Toxin 69 Cytotoxic 69 Metastatic Melanoma 69 Inflammatory Disease 69 Receives Fast Track 69 Analogs 69 Universal Flu Vaccine 69 Hormone Refractory Prostate Cancer 69 Immune Cells 68 Demonstrates Sustained 68 Issued Patent 68 Insulin Resistance 68 Earns Milestone Payment 68 Aganocide 68 Newly Identified 68 Macrophage 68 Biomolecules 68 Receptor Antagonists 68 Blood Clotting 68 Neural Stem Cell 68 Replacement Therapy 68 Genotypes 68 Hepatitis C Virus 68 Peripheral Blood 68 Differentially 68 Shows Efficacy 68 Cardiac Function 68 Growth Hormone Deficiency 68 Brain Cells 68 Benign Prostatic Hyperplasia 68 Novel Anti Inflammatory 68 Gene Expression Analysis 68 mertansine 68 Scientists Uncover 68 Chronic Hepatitis C 68 Protein Linked 68 Randomized Clinical Trial 68 Vascular Inflammation 68 Therapeutic Competitors Report 68 Tumor Necrosis Factor 68 Parathyroid Hormone 68 Receives CE Marking 68 Allogeneic 68 Proves Effective 68 agonistic human 68 Salivary 68 Cytochrome P# 68 Polymerase 68 Genes Identified 68 Ligands 68 Modulates 68 Chemotherapeutic Agents 68 EntreMed Presents 68 Cancer Treatments 68 Monoclonal antibody 68 Researchers Identify 68 Upregulation 68 Prostate Cancer Patients 68 IL# PE#QQR 68 BiTE Antibody 68 Study Demonstrates 68 Double Blind Placebo 68 Significantly Improved 68 Inflammatory Diseases 68 Appears Safe 68 Alfacell proprietary ribonuclease 68 biologic therapeutics 68 Asthma Treatment 68 Tumor Suppressor Gene 68 Study Shows Benefits 68 Radiation Induced 68 Lyophilized 68 Investigational Drug 68 Identifies Potential 68 Antithrombin 68 Generic Version 68 Atopic Dermatitis 68 Develops Novel 68 Metabolic Disease 68 Oncolytic Reovirus 68 Lupus Nephritis 68 Announce License Agreement 68 Gene Mutations 68 Tuberculosis Vaccine 68 Myeloma Patients 68 Anticancer Activity 68 Hepatocellular 68 Cancer Vaccine 68 Suppresses 68 Lung Cancer Vaccine 68 Chronic Myeloid Leukemia 68 Pivotal Trials 68 PKC# 68 Bird Flu Vaccine 68 Leukemias 68 Elagolix 68 Myolimus 68 Single Dose 68 Viral Infections 68 Assay Kits 68 Cytotoxic T 68 Osteoporosis Drugs 68 II Clinical Trial 68 Small Molecules 68 Patent Broadly Covering 68 oral prodrug 68 Lanthanum Carbonate 68 Oral Mucositis 68 Companion Diagnostic 68 Maribavir 68 Lowers Risk 68 Well Tolerated 68 Chemotherapeutic 68 candidates Azedra TM 68 AAG geldanamycin analog 68 Gastrointestinal Stromal Tumors 68 Drug Coated Stent 68 Epithelial 68 MKC# MKC# PP 68 Glucocorticoid 68 Genetic Variations 68 Clinical Trial Evaluating 68 Eukaryotic 68 Inhaled Corticosteroids 68 Further Validates 68 Vaccine Protects Against 68 Malignant Melanoma 68 Schizophrenia Treatment 68 Induced Pluripotent Stem Cells 68 Node Positive 68 Sunesis Pharma 68 See CLINICAL PHARMACOLOGY 68 Clinical Trial Enrollment 68 Detect Cancer 68 anti CD3 68 Targeted Therapies 68 Unfractionated Heparin 68 Treatment Shows Promise 68 Rheumatoid Arthritis Patients 68 Phenotypes 68 alpha#beta# integrin 68 Conjugated 68 protein tyrosine phosphatase 1B 68 Receives FDA Clearance 68 Stent Coating 68 Inc Therapeutic Competitors 68 Receives Complete Response 68 Non Invasive Treatment 68 Genetic Predisposition 68 Hematological Malignancies 68 Nicotinic 68 Novel Small Molecule 68 pralatrexate injection folate analogue 68 Oncogenic 68 Guanilib 67 Cervical Cancer Vaccine 67 Analytical Tool 67 Immunosuppression 67 Prophylactic Treatment 67 Beneficial Effects 67 Treatment Naïve 67 Prognostic Value 67 chimeric monoclonal antibody 67 Mucosal 67 Hepatitis B Vaccine 67 Locked Nucleic Acid LNA 67 Submits Biologics License Application 67 Disease Modifying 67 Synthase 67 Whole Genome Sequencing 67 pan HDAC inhibitor 67 Omacetaxine 67 Intravascular 67 Pharmaceuticals Initiates 67 Randomized Study 67 NPC 1C 67 Stapled Peptide 67 Anticancer 67 Helps Predict 67 Dendritic Cell 67 Therapeutic Competitors companiesandmarkets.com adEgemonye 67 Biocompatibility 67 SBIR Grant 67 Protein Kinase Inhibitors 67 Aflibercept 67 Fabry Disease 67 Dicer Substrate 67 accumulate preferentially 67 Nucleic Acid 67 AKT inhibitor 67 Secondary Hyperparathyroidism 67 TKB# 67 Pazopanib 67 Receptor Signaling 67 Patent Issued 67 Study Showed 67 Ozarelix 67 Cervical Dysplasia 67 Slow Progression 67 Neural Crest 67 Postdoctoral Position 67 Phase III Clinical Trials 67 Polymorphisms 67 Pandemic Flu Vaccine 67 Immunogenicity 67 vascular disrupting agents 67 DP VPA 67 Improved Survival 67 Treatment Regimen 67 Influenza Virus 67 Epstein Barr Virus EBV 67 Epitope 67 Hypertensive Patients 67 Pivotal Clinical Trial 67 Skin Cells 67 Maven Semantic 67 Efficacy Trial 67 Cardiomyocytes 67 Multipotent 67 Pathogen Detection 67 Antifungal 67 Microfluidic Device 67 Oncolytic 67 TNF Alpha 67 TLR9 agonist 67 liposomal formulation 67 DNA intercalator 67 PEGylated Fab fragment 67 Nitazoxanide 67 Fibroblast Growth Factor 67 Taro Receives 67 Stakeholder Opinions 67 Receives SFDA Approval 67 Hepatitis B Virus 67 Liver Tumors 67 Vaccine Shows Promise 67 Locked Nucleic Acid 67 Provides Clues 67 Neuroprotective 67 Pharmacokinetics PK 67 Molecular Mechanism 67 Tyrosine Kinase 67 GVAX ® 67 Adjuvanted 67 Cholesterol Drugs 67 Orally administered 67 Microfluidic Devices 67 Immune Therapy 67 PRN FDA Approves 67 candidate deforolimus 67 Subtypes 67 MicroRNA 67 HCV Protease Inhibitor 67 EGIR 67 Male Contraceptive 67 Multiple Ascending Dose 67 Advanced Prostate Cancer 67 Squalamine 67 Hypercholesterolemia 67 Vicriviroc 67 non nucleoside inhibitor 67 Low Dose 67 Mg Uk 67 Newly Diagnosed Multiple Myeloma 67 Technological Advances 67 fosbretabulin 67 Nucleotide 67 Refractory Hodgkin Lymphoma 67 Neurogenesis 67 Stem Cell Transplants 67 Human Neural Stem 67 Degarelix 67 Aggressive Prostate Cancer 67 Protein Kinase C 67 Prodarsan R 67 Elevated Levels 67 Antiviral Therapy 67 PDUFA Date 67 Prostate Cancer Treatment 67 Minimally Invasive Treatment 67 Study Sheds Light 67 SPRYCEL ® 67 RAV# 67 Metabolites 67 entitled Compositions 67 Adenosine A2A 67 telomerase therapeutic 67 poly ADP ribose polymerase 67 Successfully Treated 67 Civacir 67 Epratuzumab 67 Patients Receiving 67 PEGylated interferon 67 Interferons 67 Erectile Dysfunction Drug 67 Atypical Antipsychotic 67 VIVUS Announces 67 Holds Promise 67 Palifosfamide 67 Cites Positive 67 Taxane 67 MEK Inhibitor 67 Cancer Therapies 67 Iloperidone 67 Scientists Identify 67 Fracture Risk 67 Kinases 67 Biosynthesis 67 Weight Loss Drug 67 Placebo Controlled Trial 67 Dasatinib 67 Isolation Kit 67 Randomized Trials 67 Zinc Finger Nucleases 67 Vertebral Fractures 67 C1 Inhibitor 67 Azacitidine 67 Epithelial Cell 67 Heart Transplant Recipients 67 Somatostatin 67 Enzyme Replacement Therapy 67 Protein Biomarkers 67 Ad5FGF 4 67 platinum chemotherapeutic 67 Nilotinib 67 small molecule agonists 67 investigational humanized monoclonal antibody 67 Randomized Controlled Trials 67 Cutaneous T 67 Diagnostic Tools 67 Cathepsin S 67 Dehydrogenase 67 Polymorphism 67 novel emulsion formulation 67 Controlled Trial 67 Induces 67 Isavuconazole 67 Dose Finding 67 Hematological Cancers 67 Ovarian Cancer Patients 67 Myelodysplastic Syndromes 67 Proc Am Soc 67 VentiRx Pharmaceuticals 67 Reductase 67 Xcytrin R 67 Announces Publication 67 Self Assembling 67 targeted radiotherapeutic 67 Muscle Cells 67 Morpholino 67 Bafetinib 67 Chemoprevention 67 Integrase 67 Mesothelioma Treatment 67 matrix metalloproteases 67 Zinc Finger Nuclease 67 Protein Therapeutics 67 Novel Treatments 67 Insulin Sensitivity 67 Optimer Pharma 67 receptor tyrosine kinase inhibitor 67 Molecular Mechanisms 67 Bavituximab 67 CCR1 67 Factor VIIa 67 Lung Cancers 67 Tumor Angiogenesis 67 HER2 Positive Breast Cancer 67 Prolongs Life 67 Enrolls First 67 Clinical Study Shows 67 selective immunoproteasome inhibitor 67 Nucleic Acids 67 Slows Progression 67 Diabetic Patients 67 2 inhibitor CYT# 67 Long Term Efficacy 67 G Protein Coupled 67 oral JAK1 67 Cocaine Addiction 67 miRview meso 67 CD# CEA 67 Pandemic Influenza Vaccine 67 Quark Biotech Inc. 67 Advanced Colorectal Cancer 67 Previously Treated 67 Begins Shipment 66 Study Casts Doubt 66 mda 7 66 NS5b 66 lipid nanoparticle 66 Adult Stem Cell Therapy 66 Cetrorelix 66 Pulmonary Arterial Hypertension 66 FDA Clearance 66 Lenocta 66 Tesamorelin 66 Adjunctive Therapy 66 Less Invasive 66 Skin Lesions 66 Biolimus A9 66 Prostate AdenoCarcinoma Treatment 66 Reveals Positive 66 Autoimmune Disorders 66 Bone Metastases 66 Intravenous Human 66 Uses Thereof 66 Proven Effective 66 Investigational Oral 66 Thyroid Hormone 66 Pandemic Influenza Vaccines 66 Epeius Biotechnologies Corporation 66 Secretase 66 Androgen Receptor 66 Expand Collaboration 66 Novel Anticancer 66 Mol Cell 66 Neuroendocrine Tumors 66 Curaxin 66 Mycophenolate Mofetil 66 Inactivation 66 Shown Effective 66 Bioresorbable 66 Antidepressant Drug 66 thalidomide Thalomid 66 Tigecycline 66 Myocardial Ischemia 66 Archexin 66 Tr DNA 66 Chronic Hepatitis B 66 Fewer Side Effects 66 Cell Derived 66 demethylating agent 66 Rigel R# 66 small molecule thrombopoietin 66 Nuvelo Announces 66 Patients Enrolled 66 Denufosol 66 Complicated Skin 66 Metastatic Renal Cell Carcinoma 66 replicon 66 Onyx Pharmaceuticals Announces 66 visit www.genenews.com 66 Apaziquone 66 Microtubule 66 Chronic Inflammation 66 Molecular Cancer 66 Methylnaltrexone 66 Nat Clin Pract 66 Topline Results 66 Secretion 66 Pharmacogenomic 66 XL# XL# 66 Tissue Engineered 66 Cethromycin 66 Corautus Genetics 66 Xanafide 66 Multiple Myeloma Patients 66 Commercialize 66 Obtains License 66 Premature Aging 66 Protease Inhibitors 66 Meta Analysis 66 Prostate Cancer Cells 66 Genes Associated 66 tubulin inhibitor 66 Treated Patients 66 proprietary PEGylation 66 Treat Heart Failure 66 Tyrosine Kinase Inhibitors 66 SMaRT ™ 66 Tß4 66 Pertuzumab 66 Testosterone Gel 66 Renin Inhibitor 66 HCV polymerase 66 NMDA Receptor 66 Insulin Delivery 66 Innate Immunity 66 Ovarian Cancer Treatment 66 Potent Anti 66 small molecule tyrosine 66 Help Predict 66 Prostate Tumors 66 Soluble CD# 66 Temsirolimus 66 Patients Suffering 66 Dose Response 66 Chronic Lymphocytic Leukemia 66 targeted antifolate 66 Generic Versions 66 Spectrum Pharmaceuticals Announces 66 Janus Kinase 66 TO AVOID PREGNANCY WHILE 66 agonist compounds 66 TRACON Pharmaceuticals 66 Taligen Therapeutics 66 Stent Restenosis 66 Imaging Techniques 66 Custirsen 66 Doripenem 66 Pharmacyclics Announces 66 DGAT 66 Coronary Arteries 66 Announces Tentative Approval 66 Asthma COPD 66 Plaque Psoriasis 66 Multicenter Phase 66 Announces Initiation 66 Wound Dressing 66 acetonide FA 66 Crystallographic 66 Files Provisional 66 product platforms AZX# 66 neuronal nicotinic receptor NNR 66 Live Attenuated 66 CINtec R 66 Tomorrow Cures 66 Percutaneous Tibial Nerve Stimulation 66 peptibody 66 Receptors GPCRs 66 Intradermal 66 ORLive Presents 66 TLR9 agonists 66 Genetic Tests 66 Embolic Protection 66 Hepatic Encephalopathy